Drugs / SPH1188-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03231475 | Jul 2017 → Dec 2020 | non-small cell lung carcinoma | Shanghai Pharmaceuticals Holding Co., Ltd | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH1188-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03231475 ↗ |
| Route | Oral | “qd.po” NCT03231475 ↗ |